Development of lysozyme loaded microneedles for dermal applications

Panda, Apoorva; Shettar, Abhishek; Sharma, Pravin Kumar; Repka, Michael A.; Murthy, S. N. B.

doi:10.1016/j.ijpharm.2020.120104

Cited by 29 publications

(12 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At the same time, it can maintain the biological activity of certain peptides and proteins (Du et al., 2021a ; Fonseca et al., 2019 ). It also allows for a sustained and relatively rapid release of enzymes (Di Natale et al., 2021 ; Panda et al., 2021 ) and antibodies (Monkare et al., 2015 ).…”

Section: Characteristics Of Ha As a Mnp Materialsmentioning

confidence: 99%

See 1 more Smart Citation

The most promising microneedle device: present and future of hyaluronic acid microneedle patch

et al. 2022

View full text Add to dashboard Cite

Microneedle patch (MNP) is an alternative to the oral route and subcutaneous injection with unique advantages such as painless administration, good compliance, and fewer side effects. Herein, we report MNP as a prominent strategy for drug delivery to treat local or systemic disease. Hyaluronic acid (HA) has advantageous properties, such as human autologous source, strong water absorption, biocompatibility, and viscoelasticity. Therefore, the Hyaluronic acid microneedle patch (HA MNP) occupies a large part of the MNP market. HA MNP is beneficial for wound healing, targeted therapy of certain specific diseases, extraction of interstitial skin fluid (ISF), and preservation of drugs. In this review, we summarize the benefits of HA and cross-linked HA (x-HA) as an MNP matrix. Then, we introduce the types of HA MNP, delivered substances, and drug distribution. Finally, we focus on the biomedical application of HA MNP as an excellent drug carrier in some specific diseases and the extraction and analysis of biomarkers. We also discuss the future development prospect of HA MNP in transdermal drug delivery systems (TDDS).

show abstract

Section: Characteristics Of Ha As a Mnp Materialsmentioning

confidence: 99%

“…In addition. HA MNP has the ability and potential to encapsulate proteins, enzymes, and antibodies within a polymeric matrix, maintaining the bioactive structure of certain peptides and proteins (Panda et al., 2021 ). For example, MeHA can stabilize peptides and HA can stabilize lysozyme.…”

Section: Delivery Of Substancesmentioning

confidence: 99%

The most promising microneedle device: present and future of hyaluronic acid microneedle patch

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Newly developed nanomaterials can improve transdermal drug absorption. Following advances in micro/nanofabrication technologies, different microneedles were developed to effectively deliver different drugs. − Although these drug-loaded microneedles painlessly crossed the stratum corneum and efficaciously and directly delivered drugs, many technical challenges hindered drug loading efficiency, such as residual microneedles remaining in skin tissue . Recently, nanocarriers with good loading capacity and transdermal performance were developed to treat dermatological diseases; − however, further studies are required to improve the biocompatibility and degradability of existing transdermal nanocarriers.…”

Section: Introductionmentioning

confidence: 99%

Silk Nanocarrier with Tunable Size to Improve Transdermal Capacity for Hydrophilic and Hydrophobic Drugs

Wang

Liu

et al. 2023

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

Transdermal drug delivery is an attractive option for multiple disease therapies as it reduces adverse reactions and improves patient compliance. Water-dispersible β-sheet rich silk nanofiber carriers have hydrophobic properties that benefit transdermal delivery but still show inferior transdermal capacities. Thus, hydrophobic silk nanofibers were fabricated to fine-tune their size and endow them with desirable transdermal delivery capacities. Silk nanocarrier length was shortened from 2000 nm to approximately 40 nm after ultrasonic treatment. In vitro human skin and in vivo animal studies revealed different transdermal behaviors for silk nanocarriers at different nanosizes. Silk nanocarriers passed slowly through the corneum without destroying the corneum structure. Improved transdermal capacity was achieved for smaller size carriers. Both hydrophilic and hydrophobic drugs could be loaded onto silk nanocarriers, suggesting a promising future for different disease therapies. No cytotoxicity and skin irritation were identified for silk nanocarriers, which strengthened their superiority as transdermal carriers. Therefore, silk nanocarriers <100 nm may promote the percutaneous absorption of active cargos for disease therapy and cosmetic applications.

show abstract

“…[ 14 ] PVP MNs have demonstrated the ability to encapsulate various drugs within their polymeric matrix, and have shown stability after short‐term stability studies. [ 15 ] PMVE–MA is a commonly used material in hydrogel‐forming MNs and has been cross‐linked with various materials as reported in literature. [ 16 ]…”

Section: Introductionmentioning

confidence: 99%

Double‐Layered Polyvinylpyrrolidone–Poly(methyl vinyl ether‐alt‐maleic acid)‐Based Microneedles to Deliver Meloxicam: An In Vitro, In Vivo, and Short‐Term Stability Evaluation Study

D'Amico

Fontana

El‐Sayed

et al. 2023

Advanced Therapeutics

View full text Add to dashboard Cite

This study aims to explore the use of polymeric microneedles (MNs) for the transdermal delivery of drugs, a noninvasive and convenient method that avoids first-pass metabolism and gastrointestinal complications. Specifically, a double-layered MN formulation is developed using polyvinylpyrrolidone and cross-linked poly(methyl vinyl ether-alt-maleic acid), comprising a dissolvable layer and a hydrogel-forming layer. Meloxicam serves as the model drug, and no organic solvents are employed in the manufacturing process to reduce toxicity. Coherent anti-Stokes Raman spectroscopy (CARS) is utilized to confirm that the manufacturing process does not alter the drug's physical properties. In vitro and ex vivo studies demonstrate that the double-layered MN formulation exhibits faster drug release in the first few hours, followed by a slower release. This results in extended bioavailability in vivo compared to the commercial oral formulation of meloxicam. Preliminary results indicate that the MN formulation is also effective in pain relief and inflammation reduction. The short-term stability of the MN formulation is also confirmed, including its mechanical properties, sustained skin permeability, drug physical properties and distribution within MNs using CARS microscopy. Overall, these results suggest that the double-layered MN formulation holds significant potential for transdermal drug delivery, offering a safer and more effective alternative to traditional oral administration.

show abstract

Development of lysozyme loaded microneedles for dermal applications

Cited by 29 publications

References 32 publications

The most promising microneedle device: present and future of hyaluronic acid microneedle patch

The most promising microneedle device: present and future of hyaluronic acid microneedle patch

Silk Nanocarrier with Tunable Size to Improve Transdermal Capacity for Hydrophilic and Hydrophobic Drugs

Double‐Layered Polyvinylpyrrolidone–Poly(methyl vinyl ether‐alt‐maleic acid)‐Based Microneedles to Deliver Meloxicam: An In Vitro, In Vivo, and Short‐Term Stability Evaluation Study

Contact Info

Product

Resources

About